News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Release: First Phase III Data on Innovative Compound for Solid Organ Transplantation To be Featured at American Transplant Congress



5/28/2009 1:18:23 PM

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that belatacept, an investigational co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of nine company-sponsored clinical presentations at the upcoming American Transplant Congress to be held May 30 to June 3 in Boston. Belatacept is in phase III development.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES